凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
上海医药(601607)公告正文

上海医药:2015年第三季度报告

公告日期 2015-10-30
股票简称:上海医药 股票代码:601607
                           2015 年第三季度报告



公司代码:601607                                 公司简称:上海医药




                   上海医药集团股份有限公司
                     2015 年第三季度报告




                                 1 / 20
                                 2015 年第三季度报告




                                    目录
一、   重要提示 .................................................................. 3
二、   公司主要财务数据和股东变化 ................................................ 4
三、   重要事项 .................................................................. 7
四、   附录...................................................................... 9




                                       2 / 20
                                         2015 年第三季度报告




一、 重要提示


1.1 公司董事会、监事会及董事、监事、高级管理人员应当保证季度报告内容的真实、准确、完

     整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。



1.2 公司全体董事出席于 2015 年 10 月 29 日召开的第五届董事会第十九次会议,会议通过的决议

     包括批准本公司截至 2015 年 9 月 30 日止九个月之第三季度业绩。



1.3 公司负责人楼定波、主管会计工作负责人左敏及会计机构负责人(会计主管人员)沈波保证

     季度报告中财务报表的真实、准确、完整。



1.4 本公司第三季度报告未经审计。


1.5 释义
    本报告中,除非文义另有所指,相关财务数据均为根据中国企业会计准则等规定编制,下列
词语具有下述含义:
 “本公司”、“公司”或“上海医        上海医药集团股份有限公司或上海医药集团股份有限公司
                                  指
 药”                                  及其子公司如适用
 “报告期”                       指   2015 年 7 月 1 日至 2015 年 9 月 30 日的 3 个月
 “同比”                         指   与上年同期比较
 “股份”                         指   上海医药每股面值人民币 1.00 元的股份,包括 A 股和 H 股
                                       在上海证券交易所上市、并以人民币买卖的本公司内资股,
 “A 股”                         指
                                       每股面值人民币 1.00 元
                                       在香港联合交易所有限公司上市、并以港元买卖的本公司
 “H 股”                         指
                                       外资股,每股面值人民币 1.00 元
 “人民币”                       指   中国法定货币人民币
 “港元”                         指   香港法定货币港元
                                       中华人民共和国,除另有所指外,在本报告内“中国”一
 “中国”                         指
                                       词不包括香港、澳门及台湾
 “香港”                         指   香港特别行政区




                                               3 / 20
                                        2015 年第三季度报告




 二、 公司主要财务数据和股东变化


 2.1 主要财务数据
                                                                             单位:元      币种:人民币
                                                                                     本报告期末比上年度
                                    本报告期末                  上年度末
                                                                                         末增减(%)
总资产                         72,486,196,073.32               64,340,558,156.78                     12.66
归属于上市公司股东的净资产     29,107,048,830.98               27,822,129,424.69                      4.62
                               年初至报告期末             上年初至上年报告期末
                                                                                     比上年同期增减(%)
                                 (1-9 月)                     (1-9 月)
经营活动产生的现金流量净额          670,197,580.67               740,485,653.27                      -9.49
                               年初至报告期末             上年初至上年报告期末          比上年同期增减
                                 (1-9 月)                     (1-9 月)                  (%)
营业收入                       79,040,339,101.51               68,715,987,409.43                     15.02
归属于上市公司股东的净利润      2,178,822,695.48                1,912,585,778.79                     13.92
归属于上市公司股东的扣除非
                                2,054,325,446.25                1,706,356,609.39                     20.39
经常性损益的净利润
加权平均净资产收益率(%)                     7.63                            7.21    增加 0.42 个百分点
基本每股收益(元/股)                      0.8103                          0.7113                    13.92
稀释每股收益(元/股)                      0.8103                          0.7113                    13.92



 非经常性损益项目和金额
 √适用 □不适用
                                                                               单位:元     币种:人民币
                                                                             本期金额       年初至报告期末
                             项目
                                                                           (7-9 月)      金额(1-9 月)
非流动资产处置损益                                                          7,583,961.09       14,918,418.53
计入当期损益的政府补助,但与公司正常经营业务密切相关,符合
                                                                           15,573,379.79      114,793,611.28
国家政策规定、按照一定标准定额或定量持续享受的政府补助除外
除同公司正常经营业务相关的有效套期保值业务外,持有交易性金
融资产、交易性金融负债产生的公允价值变动损益,以及处置交易                   -101,640.00           82,836.60
性金融资产、交易性金融负债和可供出售金融资产取得的投资收益
单独进行减值测试的应收款项减值准备转回                                                          3,854,140.00
除上述各项之外的其他营业外收入和支出                                       47,390,265.70       48,023,789.39
所得税影响额                                                            -18,323,560.74        -42,937,813.91
少数股东权益影响额(税后)                                                 -6,097,362.70      -14,237,732.66
                             合计                                          46,025,043.14      124,497,249.23

 报告期内公司经营情况及业绩分析



                                                 4 / 20
                                    2015 年第三季度报告


    2015 年 1-9 月,本公司实现营业收入人民币 790.40 亿元,同比增长 15.02%;实现归属于母公
司股东的净利润人民币 21.79 亿元,同比上升 13.92%;扣除非经常性损益后的归属于母公司净利
润为人民币 20.54 亿元,同比增长 20.39%,完成 2015 年三季度预算指标。
    报告期内,上海医药入选《财富 Fortune》(中文版)发布的 2015 最受赞赏的中国医药制造
业公司第三位;入选上海市企业联合会、上海市企业家协会、上海市经济团体联合会评选的 2014
上海企业 100 强第 18 位、上海制造业 50 强第 8 位;入选中国品牌研究院发布的 2015 年中国品牌
500 强第 55 位。
    报告期内,公司在研项目正常进展,新增两个品种的临床批文 5 个,两个品种申报生产批文 2
个,两个品种申报临床批文 4 个。
     2015 年 1-9 月,本公司医药制造业务实现营业收入人民币 88.84 亿元,同比增长 6.93%,毛
利率 49.73%,扣除两项费用后营业利润率为 12.79%。其中 60 个重点产品实现销售收入人民币
49.48 亿元,同比上升 11.66%,占工业销售比重 55.70%。
    重点产品中预计全年销售收入超过人民币 1 亿元的大品种有 24 个,2015 年 1-9 月,其中增速
前五名产品的平均增速为 46.95%,增速后五名产品的平均增速为-7.96%,具体为:
                                                                  2015 年 1-9 月销售收入
   序号             产品名称                    治疗领域
                                                                     (万元人民币)
    1      参麦注射液                心血管系统                                   55,208
    2      羟氯喹                    抗肿瘤和免疫调节剂                           31,147
    3      培菲康                    消化道和新陈代谢                             29,392
    4      丹参酮 IIA                心血管系统                                   27,059
    5      二丁酰环磷腺苷钙          心血管系统                                   22,894
    6      头孢替安                  全身性抗感染药                               22,321
    7      尪痹片                    骨骼肌肉系统                                 20,500
    8      注射用头孢曲松钠          全身性抗感染药                               18,715
    9      瓜蒌皮                    心血管系统                                   15,838
    10     瑞舒伐他汀原料药          心血管系统                                   13,165
    11     养心氏                    心血管系统                                   12,312
    12     糜蛋白酶                  呼吸系统                                     11,987
    13     顺苯磺阿曲库铵            骨骼肌肉系统                                 11,721
    14     新癀片                    骨骼肌肉系统                                 11,597
    15     红源达                    血液和造血器官                               11,210
    16     乳癖消                    泌尿生殖系统和性激素                         11,107
    17     阿立哌唑                  中枢神经系统                                 10,358
    18     银杏酮酯系列              心血管系统                                   10,171
    19     清凉油                    其他                                          9,797
    20     注射用头孢噻肟钠          全身性抗感染药                                9,746
    21     胃复春片                  消化道和新陈代谢                              9,390
    22     沙利度胺                  抗肿瘤和免疫调节剂                            9,136
    23     度洛西汀                  中枢神经系统                                  8,677
    24     八宝丹                    消化道和新陈代谢                              6,737

    2015 年 1-9 月,本公司医药服务业务中,医药分销业务实现营业收入人民币 698.24 亿元,同
比增长 16.00%,毛利率 5.92%,扣除两项费用后营业利润率为 2.74%;药品零售业务实现营业收
入人民币 35.05 亿元,同比增长 14.00%,毛利率 15.48%,扣除两项费用后营业利润率为 1.31%。


                                            5 / 20
                                           2015 年第三季度报告




     2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
                                                                                                  单位:股
股东总数(户)                                                                                            90,403
                                          前十名股东持股情况
           股东名称        期末持股数      比例     持有有限售条          质押或冻结情况            股东性质
           (全称)            量          (%)        件股份数量       股份状态        数量
HKSCC NOMINEES LIMITED     748,135,320     27.82                   0       未知                            外资
上海医药(集团)有限公司     716,516,039     26.65                   0       质押      13,648,772      国有法人
上海实业(集团)有限公司
                                                                                                   国有法人及
及其全资附属子公司及上海   238,586,198      8.87                   0       未知
                                                                                                         外资
上实(集团)有限公司
申能(集团)有限公司          81,199,520      3.02                   0       未知                      国有法人
中国证券金融股份有限公司    80,399,943      2.99                   0       未知                            未知
上海盛睿投资有限公司        65,659,190      2.44                   0       未知                      国有法人
中央汇金投资有限责任公司    24,891,300      0.93                   0       未知                            未知
全国社保基金六零四组合      19,353,378      0.72                   0       未知                            未知
中国农业银行股份有限公司
-富国中证国有企业改革指    15,409,770      0.57                   0       未知                            未知
数分级证券投资基金
香港中央结算有限公司        13,833,312      0.51                   0       未知                            未知
                                   前十名无限售条件股东持股情况
股东名称                              持有无限售条件流通股                        股份种类及数量
                                              的数量                       种类                    数量
HKSCC NOMINEES LIMITED                               748,135,320       境外上市外资股              748,135,320
上海医药(集团)有限公司                               716,516,039         人民币普通股              716,516,039
上海实业(集团)有限公司及其全资附                                       人民币普通股              222,301,798
                                                     238,586,198
属子公司及上海上实(集团)有限公司                                     境外上市外资股               16,284,400
申能(集团)有限公司                                    81,199,520         人民币普通股               81,199,520
中国证券金融股份有限公司                              80,399,943         人民币普通股               80,399,943
上海盛睿投资有限公司                                  65,659,190         人民币普通股               65,659,190
中央汇金投资有限责任公司                              24,891,300         人民币普通股               24,891,300
全国社保基金六零四组合                                19,353,378         人民币普通股               19,353,378
中国农业银行股份有限公司-富国中证
                                                      15,409,770         人民币普通股               15,409,770
国有企业改革指数分级证券投资基金
香港中央结算有限公司                                  13,833,312         人民币普通股               13,833,312
上述股东关联关系或一致行动的说明      上海实业(集团)有限公司为上海上实(集团)有限公司实际控制
                                      人,上海上实(集团)有限公司为上海医药(集团)有限公司控股股
                                      东。本公司未知其他股东之间是否存在关联关系或是否属于《上市
                                      公司股东持股变动信息披露管理办法》规定的一致行动人。
表决权恢复的优先股股东及持股数量的    /
说明
     注:截止报告期末股东总数 90,403 户中,A 股 87,983 户;H 股 2,420 户。
                                                   6 / 20
                                               2015 年第三季度报告



       2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情
           况表

       □适用 √不适用



       三、 重要事项


       3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
       √适用 □不适用
                                                                                 单位:元   币种:人民币
合并资产负债表项目     2015 年 9 月 30 日   2014 年 12 月 31 日      变动比例               变动原因
                                                                                 本报告期内主营业务收入增长及
应收账款               26,212,187,904.00     19,941,255,695.95         31.45%
                                                                                       合并范围增加所致
                                                                                 本报告期内预付原材料款项及合
预付款项                1,457,743,840.03       1,076,062,833.82        35.47%
                                                                                       并范围增加所致
应收利息                    4,690,107.68           9,341,136.00        -49.79%       本报告期预提利息减少

应收股利                   12,101,696.81        274,730,002.86         -95.60%   本报告期应收联营企业股利减少

                                                                                 本报告期新增可供出售金融资产
可供出售金融资产          247,406,084.19        187,433,250.57         32.00%
                                                                                             投资
在建工程                1,163,559,123.25        632,603,481.79         83.93%     本报告期内购建长期资产增加

生产性生物资产            395,094,857.50            584,595.29    67,484.34%       本报告期内收购子公司增加

预收款项                  320,227,850.51        515,773,646.56         -37.91%      本报告期内预收货款减少
一年内到期的非流动
                           27,435,856.17         20,730,000.00         32.35%      本报告期内收购子公司增加
负债
 预计负债                  29,739,831.29         13,655,716.53        117.78%     本报告期内合并范围增加所致

  合并利润表项目        2015 年 1-9 月         上年同期数            变动比例               变动原因
                                                                                 本报告期内利息支出增加及利息
财务费用                  445,584,336.49        325,258,076.26         36.99%
                                                                                           收入减少
                                                                                 本报告期内计提的资产减值损失
资产减值损失              113,094,739.46         67,099,543.13         68.55%
                                                                                             增加
                                                                                 报告期内处置拆迁及其他补偿款
营业外收入                217,885,328.04        313,410,359.03         -30.48%
                                                                                             减少
营业外支出                 47,119,714.76        124,733,864.75         -62.22%     报告期内处置拆迁支出减少

合并现金流量表项目      2015 年 1-9 月         上年同期数            变动比例               变动原因
经营活动产生的现金                                                               本报告期内业务扩大,资金流出增
                          670,197,580.67        740,485,653.27          -9.49%
流量净额                                                                                       加

                                                     7 / 20
                                            2015 年第三季度报告



投资活动产生的现金
                     -1,450,028,524.89     -1,628,764,298.49         /       本报告期内投资性流出减少
流量净额
筹资活动产生的现金
                         -112,114,486.52   -1,115,043,897.04         /          本报告期内取得借款增加
流量净额




       3.2 重要事项进展情况及其影响和解决方案的分析说明
       √适用 □不适用
            1、就漳州片仔癀药业股份有限公司(简称“片仔癀”)向漳州市中级人民法院(简称“漳州
       中院”)起诉厦门中药厂有限公司(简称“厦门中药厂”)、厦门晚报传媒发展有限公司和厦门日报
       社不正当竞争纠纷一案,厦门中药厂于 2014 年 3 月 13 日向漳州中院提出管辖权异议申请,同年
       4 月 4 日,厦门中药厂收到(2014)漳民初字第 35-3 号《民事裁定书》,漳州中院一审裁定驳回
       厦门中药厂对本案管辖权提出的异议。 2014 年 4 月 13 日,厦门中药厂向福建省高级人民法院(简
       称“福建高院”)提出管辖权异议上诉申请,同年 6 月 23 日,福建高院以(2014)闽民终字第 660
       号《民事裁定书》终审裁定撤销漳州中院(2014)漳民初字第 35-3 号民事裁定,并将本案移送至
       厦门市中级人民法院(简称“厦门中院”)管辖。2014 年 8 月 18 日,厦门中药厂收到(2014)厦
       民初字第 937 号《福建省厦门市中级人民法院通知书》,通知称,福建高院又将本案指定由福州市
       中级人民法院(简称“福州中院”)管辖。2014 年 10 月 22 日,厦门中药厂收到福州中院关于本
       案举证期限延迟至 2014 年 11 月 7 日的通知书。2014 年 12 月 5 日,厦门中药厂收到福州中院送
       达的《合议庭组成人员通知书》和片仔癀提交的《起诉状》,片仔癀对原先的起诉状进行了部分调
       整。2014 年 12 月 19 日,厦门中药厂以原告诉请调整后超过级别管辖为由,向福州中院提出了管
       辖异议。2015 年 1 月 9 日,厦门中药厂收到(2014)榕民初字第 1431-1 号《民事裁定书》,福州
       中院一审裁定驳回厦门中药厂管辖异议申请。2015 年 1 月 19 日,厦门中药厂再次向福建高院提
       出管辖异议上诉申请。2015 年 3 月 4 日,福建高院以(2015)闽民终字第 446 号民事裁定书终审
       裁定驳回上诉,本案确定由福州中院管辖。2015 年 5 月 8 日,福州中院就本案召开庭前会议。2015
       年 8 月 3 日,福州中院再次就本案召开庭前会议。2015 年 8 月 31 日,福州中院就本案召开第三
       次庭前会议。
            2、2014 年 6 月 18 日,厦门中药厂依据相关规定,就片仔癀于 2012 年 11 月 1 日向中华人民
       共和国国家工商行政管理总局商标局(简称“国家工商总局商标局”) 申请在第 5 类“中药成药”
       等商品项目上注册的“八宝丹片仔癀” 申请号:11683990)和“片仔癀八宝丹” 申请号:11683929)
       商标,向国家工商总局商标局提交了商标异议申请,请求国家工商总局商标局驳回该两件被异议
       商标的注册申请,现该事宜仍处于商标异议审查程序中。
           3、2015 年 8 月 17 日,厦门中药厂向福州中院提交了诉片仔癀、福州回春医药连锁有限公司
       火车站医药商店(简称“回春医药火车站店”)、福州回春医药连锁有限公司(简称“回春医药”)
       不正当竞争的起诉状,请求判令片仔癀立即停止侵犯厦门中药厂 “八宝丹”系列产品品牌的虚假
       宣传行为;赔偿厦门中药厂经济损失和合理维权费用人民币 299.7 万元;在省级以上报刊及其官
       方网站上连续 6 个月公开发布声明,澄清事实,消除因其虚假宣传给厦门中药厂造成的不良影响;
       请求判令回春医药火车站店和回春医药连带赔偿厦门中药厂经济损失人民币 3,000 元;请求判令
       三被告共同承担本案的全部诉讼费用。福州中院于当日立案受理,案号为(2015)榕民初字第 1518
       号。片仔癀在提交答辩状期间向福州中院提出管辖权异议。2015 年 9 月 22 日,福州中院裁定驳
       回片仔癀对本案管辖权提出的异议。



       3.3 公司及持股 5%以上的股东承诺事项履行情况
       √适用 □不适用



                                                  8 / 20
                                    2015 年第三季度报告



    详见本公司《关于实际控制人、股东、关联方、收购人以及公司承诺及履行情况公告》(公司
公告临2014-001号)、《关于控股股东增持本公司股份的公告》(公司公告临2014-012)、《承
诺解决进展公告》(公司公告临2014-017号)、《关于控股股东增持公司股份实施期限届满的公
告》(公司公告临2015-016号)和《关于维护公司股价稳定的公告》(公司公告临2015-023号)。



3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警

    示及原因说明
□适用 √不适用



                                                                       上海医药集团股份有限公
                                                          公司名称
                                                                       司
                                                       法定代表人      楼定波
                                                               日期    2015-10-29




四、 附录


4.1 财务报表
                                      合并资产负债表
                                     2015 年 9 月 30 日
编制单位:上海医药集团股份有限公司

                                               单位:元       币种:人民币   审计类型:未经审计
                  项目                             期末余额                     年初余额
流动资产:
  货币资金                                         10,737,422,008.82            11,608,054,131.64
  结算备付金
  拆出资金
  以公允价值计量且其变动计入当期损                        588,495.60                  505,659.00
益的金融资产
  衍生金融资产
  应收票据                                          1,157,625,324.45             1,466,422,850.39
  应收账款                                         26,212,187,904.00            19,941,255,695.95
  预付款项                                          1,457,743,840.03             1,076,062,833.82
  应收保费
  应收分保账款
  应收分保合同准备金
  应收利息                                              4,690,107.68                 9,341,136.00

                                          9 / 20
                                 2015 年第三季度报告



  应收股利                                         12,101,696.81      274,730,002.86
  其他应收款                                      822,063,717.60      827,130,409.52
  买入返售金融资产
  存货                                        13,865,617,575.68     13,088,152,517.58
  划分为持有待售的资产                                                 10,723,975.38
  一年内到期的非流动资产
  其他流动资产                                    338,667,184.88      355,940,975.59
    流动资产合计                              54,608,707,855.55     48,658,320,187.73
非流动资产:
  发放贷款及垫款
  可供出售金融资产                                247,406,084.19      187,433,250.57
  持有至到期投资
  长期应收款                                      294,219,646.04      252,911,978.93
  长期股权投资                                   3,392,325,076.56    2,745,612,375.88
  投资性房地产                                    283,991,793.28      295,476,451.38
  固定资产                                       4,329,147,041.21    4,360,757,587.08
  在建工程                                       1,163,559,123.25     632,603,481.79
  工程物资                                             298,482.89         301,316.23
  固定资产清理
  生产性生物资产                                  395,094,857.50          584,595.29
  油气资产
  无形资产                                       2,003,294,025.56    1,861,577,368.33
  开发支出
  商誉                                           4,851,427,371.87    4,473,418,643.01
  长期待摊费用                                    216,376,221.76      204,156,613.61
  递延所得税资产                                  247,556,766.25      264,590,931.01
  其他非流动资产                                  452,791,727.41      402,813,375.94
    非流动资产合计                            17,877,488,217.77     15,682,237,969.05
      资产总计                                72,486,196,073.32     64,340,558,156.78
流动负债:
  短期借款                                       9,590,323,307.88    7,932,394,326.58
  向中央银行借款
  吸收存款及同业存放
  拆入资金
  以公允价值计量且其变动计入当期损
益的金融负债
  衍生金融负债
  应付票据                                       3,407,143,131.61    3,285,913,723.61
  应付账款                                    21,461,254,771.88     17,149,970,744.54
  预收款项                                        320,227,850.51      515,773,646.56
  卖出回购金融资产款
  应付手续费及佣金
                                       10 / 20
                              2015 年第三季度报告



 应付职工薪酬                                  470,266,736.16      481,273,633.10
 应交税费                                      546,227,494.56      546,502,723.65
 应付利息                                       43,125,061.81       42,030,485.45
 应付股利                                      106,271,409.02       85,749,225.52
 其他应付款                                   2,520,802,939.81    1,942,206,837.85
 应付分保账款
 保险合同准备金
 代理买卖证券款
 代理承销证券款
 划分为持有待售的负债
 一年内到期的非流动负债                         27,435,856.17       20,730,000.00
 其他流动负债
   流动负债合计                            38,493,078,559.41     32,002,545,346.86
非流动负债:
 长期借款                                       84,777,373.67      105,408,373.67
 应付债券
 其中:优先股
        永续债
 长期应付款                                     34,164,945.10
 长期应付职工薪酬                               67,666,286.04       70,472,127.38
 专项应付款                                         540,000.00         540,000.00
 预计负债                                       29,739,831.29       13,655,716.53
 递延收益                                      537,169,162.27      554,263,213.86
 递延所得税负债                                386,572,641.19      380,162,990.98
 其他非流动负债                                144,012,802.62      114,358,625.05
   非流动负债合计                             1,284,643,042.18    1,238,861,047.47
     负债合计                              39,777,721,601.59     33,241,406,394.33
所有者权益:
 股本                                         2,688,910,538.00    2,688,910,538.00
 其他权益工具
 其中:优先股
        永续债
 资本公积                                  14,046,429,201.98     14,152,456,264.19
 减:库存股
 其他综合收益                                    6,123,790.49       12,795,675.25
 专项储备
 盈余公积                                      958,643,752.75      958,643,752.75
 一般风险准备
 未分配利润                                11,406,941,547.76     10,009,323,194.50
 归属于母公司所有者权益合计                29,107,048,830.98     27,822,129,424.69
 少数股东权益                                 3,601,425,640.75    3,277,022,337.76
   所有者权益合计                          32,708,474,471.73     31,099,151,762.45
                                    11 / 20
                                    2015 年第三季度报告



      负债和所有者权益总计                       72,486,196,073.32          64,340,558,156.78


法定代表人:楼定波         主管会计工作负责人:左敏              会计机构负责人:沈波



                                     母公司资产负债表
                                     2015 年 9 月 30 日
编制单位:上海医药集团股份有限公司
                                                单位:元     币种:人民币 审计类型:未经审计
                 项目                            期末余额                  年初余额
流动资产:
  货币资金                                          3,973,387,521.57         2,495,427,524.95
  以公允价值计量且其变动计入当期损
益的金融资产
  衍生金融资产
  应收票据
  应收账款                                                                     53,630,546.97
  预付款项                                             1,303,477.75
  应收利息                                            28,427,921.44            23,272,315.27
  应收股利                                           347,799,770.39           170,487,336.04
  其他应收款                                        4,030,954,434.82         4,303,528,593.90
  存货
  划分为持有待售的资产                                                         10,723,975.38
  一年内到期的非流动资产
  其他流动资产                                        20,659,036.78              3,364,333.18
    流动资产合计                                    8,402,532,162.75         7,060,434,625.69
非流动资产:
  可供出售金融资产                                    41,147,964.86            32,527,948.27
  持有至到期投资
  长期应收款
  长期股权投资                                   17,867,495,209.88          17,388,704,239.75
  投资性房地产
  固定资产                                            92,370,605.95           118,106,128.96
  在建工程                                            25,716,357.31            16,716,745.78
  工程物资
  固定资产清理
  生产性生物资产
  油气资产
  无形资产                                            47,428,027.82            38,286,587.88
  开发支出
  商誉
  长期待摊费用                                         8,251,328.15              9,152,753.71

                                          12 / 20
                                 2015 年第三季度报告



  递延所得税资产
  其他非流动资产
    非流动资产合计                           18,082,409,493.97      17,603,494,404.35
      资产总计                               26,484,941,656.72      24,663,929,030.04
流动负债:
  短期借款                                       1,300,000,000.00     360,000,000.00
  以公允价值计量且其变动计入当期损
益的金融负债
  衍生金融负债
  应付票据
  应付账款                                          6,979,756.56         4,093,800.18
  预收款项                                          5,489,151.57       22,207,189.17
  应付职工薪酬                                         122,028.54      13,037,231.21
  应交税费                                          5,891,344.84         5,414,284.49
  应付利息                                          1,484,108.02          560,000.00
  应付股利
  其他应付款                                     3,929,526,659.65    3,155,099,489.49
  划分为持有待售的负债
  一年内到期的非流动负债
  其他流动负债
    流动负债合计                                 5,249,493,049.18    3,560,411,994.54
非流动负债:
  长期借款
  应付债券
  其中:优先股
         永续债
  长期应付款
  长期应付职工薪酬
  专项应付款
  预计负债
  递延收益                                         53,724,686.62       57,464,692.65
  递延所得税负债                                   10,207,107.57         8,052,103.42
  其他非流动负债
    非流动负债合计                                 63,931,794.19       65,516,796.07
      负债合计                                   5,313,424,843.37    3,625,928,790.61
所有者权益:
  股本                                           2,688,910,538.00    2,688,910,538.00
  其他权益工具
  其中:优先股
         永续债
  资本公积                                   16,466,294,537.33      16,466,294,537.33
  减:库存股
                                       13 / 20
                                               2015 年第三季度报告



          其他综合收益                                           13,042,112.90                  6,577,100.46
          专项储备
          盈余公积                                              587,534,527.65                587,534,527.65
          未分配利润                                           1,415,735,097.47           1,288,683,535.99
               所有者权益合计                              21,171,516,813.35             21,038,000,239.43
                 负债和所有者权益总计                      26,484,941,656.72             24,663,929,030.04


        法定代表人:楼定波            主管会计工作负责人:左敏              会计机构负责人:沈波

                                                  合并利润表
                                                2015 年 1—9 月
        编制单位:上海医药集团股份有限公司
                                                         单位:元       币种:人民币   审计类型:未经审计
                                                                         年初至报告期期    上年年初至报告
                                  本期金额            上期金额
           项目                                                          末金额 (1-9 月) 期期末金额(1-9
                                  (7-9 月)          (7-9 月)
                                                                                                 月)
一、营业总收入                  28,090,262,686.33   24,702,971,084.00     79,040,339,101.51    68,715,987,409.43
其中:营业收入                  28,090,262,686.33   24,702,971,084.00     79,040,339,101.51    68,715,987,409.43
      利息收入
      已赚保费
      手续费及佣金收入
二、营业总成本                  27,294,992,954.10   24,000,833,459.72     76,544,947,625.51    66,456,706,351.57
其中:营业成本                  24,875,287,714.35   21,857,442,948.74     69,541,107,125.05    60,291,766,536.00
      利息支出
      手续费及佣金支出
      退保金
      赔付支出净额
      提取保险合同准备金净

      保单红利支出
      分保费用
      营业税金及附加               76,872,678.83       60,255,149.82        211,337,357.48        175,659,581.23
      销售费用                   1,330,251,057.67    1,220,082,562.18      3,888,275,856.96     3,536,376,840.87
      管理费用                    838,657,067.07      721,879,510.82       2,345,548,210.07     2,060,545,774.08
      财务费用                    154,151,303.24      127,865,456.07        445,584,336.49        325,258,076.26
      资产减值损失                 19,773,132.94       13,307,832.09        113,094,739.46         67,099,543.13
  加:公允价值变动收益(损
                                      -101,640.00           72,672.60             82,836.60           110,279.40
失以“-”号填列)
      投资收益(损失以“-”
                                   99,032,731.57       47,365,082.91        414,635,804.65        346,513,469.34
号填列)
      其中:对联营企业和合
                                   98,863,044.79       41,061,267.16        404,573,743.20        202,475,259.01
营企业的投资收益

                                                     14 / 20
                                           2015 年第三季度报告



      汇兑收益(损失以“-”
号填列)
三、营业利润(亏损以“-”
                               894,200,823.80     749,575,379.79    2,910,110,117.25   2,605,904,806.60
号填列)
  加:营业外收入                79,907,818.82     201,916,403.70     217,885,328.04     313,410,359.03
       其中:非流动资产处置
                                 5,424,624.23         273,502.51       9,231,712.21       2,944,220.78
利得
  减:营业外支出                17,894,990.53      74,013,346.39      47,119,714.76     124,733,864.75
       其中:非流动资产处置
                                 6,108,071.23        8,892,221.43      9,504,107.69      12,761,975.16
损失
四、利润总额(亏损总额以
                               956,213,652.09     877,478,437.10    3,080,875,730.53   2,794,581,300.88
“-”号填列)
  减:所得税费用               202,718,207.30     178,064,731.77     572,615,056.27     580,526,320.84
五、净利润(净亏损以“-”
                               753,495,444.79     699,413,705.33    2,508,260,674.26   2,214,054,980.04
号填列)
  归属于母公司所有者的净利
                               644,802,072.38     594,582,859.85    2,178,822,695.48   1,912,585,778.79

  少数股东损益                 108,693,372.41     104,830,845.48     329,437,978.78     301,469,201.25
六、其他综合收益的税后净额     -29,998,415.52        1,540,907.22      -9,679,722.13     -15,936,560.70
  归属母公司所有者的其他综
                               -28,581,072.16        1,444,111.14      -6,671,884.76     -14,182,380.33
合收益的税后净额
    (一)以后不能重分类进
损益的其他综合收益
      1.重新计量设定受益计
划净负债或净资产的变动
      2.权益法下在被投资单
位不能重分类进损益的其他综
合收益中享有的份额
    (二)以后将重分类进损
                               -28,581,072.16        1,444,111.14      -6,671,884.76     -14,182,380.33
益的其他综合收益
      1.权益法下在被投资单
位以后将重分类进损益的其他
综合收益中享有的份额
      2.可供出售金融资产公
                               -43,576,710.92        1,177,492.59     -20,907,127.46     -12,010,789.86
允价值变动损益
      3.持有至到期投资重分
类为可供出售金融资产损益
      4.现金流量套期损益的
有效部分
       5.外币财务报表折算差
                                14,995,638.76         266,618.55      14,235,242.70       -2,171,590.47

       6.其他
  归属于少数股东的其他综合      -1,417,343.36           96,796.08      -3,007,837.37      -1,754,180.37
                                                 15 / 20
                                              2015 年第三季度报告



 收益的税后净额
 七、综合收益总额                 723,497,029.27     700,954,612.55      2,498,580,952.13       2,198,118,419.34
   归属于母公司所有者的综合
                                  616,221,000.22     596,026,970.99      2,172,150,810.72       1,898,403,398.46
 收益总额
   归属于少数股东的综合收益
                                  107,276,029.05     104,927,641.56        326,430,141.41        299,715,020.88
 总额
 八、每股收益:
   (一)基本每股收益(元/股)              0.2398               0.2211              0.8103                0.7113
   (二)稀释每股收益(元/股)              0.2398               0.2211              0.8103                0.7113


          本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0 元, 上期被合并方实现
          的净利润为: 0 元。
          法定代表人:楼定波        主管会计工作负责人:左敏        会计机构负责人:沈波



                                                母公司利润表
                                               2015 年 1—9 月
          编制单位:上海医药集团股份有限公司
                                                         单位:元   币种:人民币 审计类型:未经审计
                                                                            年初至报告期 上年年初至报告
                                            本期金额           上期金额
                   项目                                                       期末金额       期期末金额
                                            (7-9 月)         (7-9 月)
                                                                              (1-9 月)     (1-9 月)
一、营业收入                                 2,584,599.16       1,663,329.81    23,801,991.63        4,145,276.08
  减:营业成本                                                                  10,970,919.38
       营业税金及附加                        4,170,195.63       1,283,712.76     6,627,202.61        4,181,232.79
       销售费用
       管理费用                             55,640,542.07      69,071,961.64   147,772,063.01      143,473,002.81
       财务费用                            -31,107,254.81       9,375,177.39   -81,520,776.85     -153,065,190.43
       资产减值损失                                                             -3,854,140.00
  加:公允价值变动收益(损失以“-”号
填列)
       投资收益(损失以“-”号填列)      282,141,126.96       8,923,473.36   924,720,080.97      619,799,375.18
       其中:对联营企业和合营企业的投资     75,415,884.53      -5,708,154.73   224,617,466.54       10,243,711.81
收益
二、营业利润(亏损以“-”号填列)         256,022,243.23     -69,144,048.62   868,526,804.45      629,355,606.09
  加:营业外收入                            21,636,873.31     110,327,737.60    38,725,070.72      120,824,363.60
       其中:非流动资产处置利得
  减:营业外支出                               415,990.88                         416,257.67
       其中:非流动资产处置损失
三、利润总额(亏损总额以“-”号填列)     277,243,125.66      41,183,688.98   906,835,617.50      750,179,969.69
    减:所得税费用
四、净利润(净亏损以“-”号填列)         277,243,125.66      41,183,688.98   906,835,617.50      750,179,969.69
五、其他综合收益的税后净额                 -10,242,500.58        214,625.09      6,465,012.44           -3,406.75
                                                    16 / 20
                                                  2015 年第三季度报告



  (一)以后不能重分类进损益的其他综合
收益
    1.重新计量设定受益计划净负债或净资
产的变动
    2.权益法下在被投资单位不能重分类进
损益的其他综合收益中享有的份额
  (二)以后将重分类进损益的其他综合收         -10,242,500.58        214,625.09     6,465,012.44         -3,406.75

    1.权益法下在被投资单位以后将重分类
进损益的其他综合收益中享有的份额
     2.可供出售金融资产公允价值变动损益        -10,242,500.58        214,625.09     6,465,012.44         -3,406.75
    3.持有至到期投资重分类为可供出售金
融资产损益
     4.现金流量套期损益的有效部分
     5.外币财务报表折算差额
     6.其他
六、综合收益总额                               267,000,625.08     41,398,314.07   913,300,629.94    750,176,562.94
七、每股收益:
     (一)基本每股收益(元/股)                   不适用            不适用           不适用            不适用
     (二)稀释每股收益(元/股)                   不适用            不适用           不适用            不适用

          法定代表人:楼定波             主管会计工作负责人:左敏             会计机构负责人:沈波



                                                   合并现金流量表
                                                   2015 年 1—9 月
          编制单位:上海医药集团股份有限公司
                                                           单位:元     币种:人民币    审计类型:未经审计
                                    项目                                 年初至报告期期      上年年初至报告
                                                                             末金额          期期末金额(1-9
                                                                           (1-9 月)              月)
         一、经营活动产生的现金流量:
              销售商品、提供劳务收到的现金                              85,992,658,962.45    72,033,534,409.75
              客户存款和同业存放款项净增加额
              向中央银行借款净增加额
              向其他金融机构拆入资金净增加额
              收到原保险合同保费取得的现金
              收到再保险业务现金净额
              保户储金及投资款净增加额
           处置以公允价值计量且其变动计入当期损益的金融资产
         净增加额
              收取利息、手续费及佣金的现金
              拆入资金净增加额
                                                        17 / 20
                                  2015 年第三季度报告



 回购业务资金净增加额
 收到的税费返还                                            40,599,614.76       26,763,933.48
 收到其他与经营活动有关的现金                             594,543,730.01      843,968,194.84
   经营活动现金流入小计                                 86,627,802,307.22   72,904,266,538.07
 购买商品、接受劳务支付的现金                           76,579,887,154.01   63,682,210,524.10
 客户贷款及垫款净增加额
 存放中央银行和同业款项净增加额
 支付原保险合同赔付款项的现金
 支付利息、手续费及佣金的现金
 支付保单红利的现金
 支付给职工以及为职工支付的现金                          2,830,260,897.04    2,602,917,802.26
 支付的各项税费                                          2,276,714,411.63    2,156,259,401.35
 支付其他与经营活动有关的现金                            4,270,742,263.87    3,722,393,157.09
   经营活动现金流出小计                                 85,957,604,726.55   72,163,780,884.80
     经营活动产生的现金流量净额                           670,197,580.67      740,485,653.27
二、投资活动产生的现金流量:
 收回投资收到的现金                                      1,509,146,651.65     404,990,451.34
 取得投资收益收到的现金                                    99,552,224.25      128,545,535.49
 处置固定资产、无形资产和其他长期资产收回的现金净额        41,766,136.36      128,777,289.39
 处置子公司及其他营业单位收到的现金净额                    28,672,816.91       38,428,138.98
 收到其他与投资活动有关的现金                             245,259,184.10      320,836,000.03
   投资活动现金流入小计                                  1,924,397,013.27    1,021,577,415.23
 购建固定资产、无形资产和其他长期资产支付的现金          1,050,552,482.69     651,252,476.74
 投资支付的现金                                          1,500,000,000.00     700,000,000.00
 质押贷款净增加额
 取得子公司及其他营业单位支付的现金净额                   590,971,931.15     1,106,293,412.96
 支付其他与投资活动有关的现金                             232,901,124.32      192,795,824.02
   投资活动现金流出小计                                  3,374,425,538.16    2,650,341,713.72
     投资活动产生的现金流量净额                         -1,450,028,524.89   -1,628,764,298.49
三、筹资活动产生的现金流量:
 吸收投资收到的现金                                        74,300,000.00         7,939,912.88
 其中:子公司吸收少数股东投资收到的现金                    74,300,000.00         7,939,912.88
 取得借款收到的现金                                     15,046,779,243.00   10,567,995,845.28
 发行债券收到的现金
 收到其他与筹资活动有关的现金                             250,627,795.86      232,277,969.10
   筹资活动现金流入小计                                 15,371,707,038.86   10,808,213,727.26
 偿还债务支付的现金                                     13,666,883,254.79    9,804,590,593.09
 分配股利、利润或偿付利息支付的现金                      1,419,557,299.11    1,339,077,290.13
 其中:子公司支付给少数股东的股利、利润                   183,775,850.46      258,730,268.01
 支付其他与筹资活动有关的现金                             397,380,971.48      779,589,741.08
   筹资活动现金流出小计                                 15,483,821,525.38   11,923,257,624.30
     筹资活动产生的现金流量净额                           -112,114,486.52   -1,115,043,897.04
                                          18 / 20
                                    2015 年第三季度报告



四、汇率变动对现金及现金等价物的影响                          -1,006,456.44       -3,645,680.97
五、现金及现金等价物净增加额                                -892,951,887.18   -2,006,968,223.23
 加:期初现金及现金等价物余额                             11,190,420,441.63   12,645,366,853.17
六、期末现金及现金等价物余额                              10,297,468,554.45   10,638,398,629.94

 法定代表人:楼定波         主管会计工作负责人:左敏           会计机构负责人:沈波



                                      母公司现金流量表
                                        2015 年 1—9 月
 编制单位:上海医药集团股份有限公司
                                              单位:元    币种:人民币   审计类型:未经审计
                         项目                              年初至报告期期     上年年初至报告
                                                               末金额         期期末金额(1-9
                                                             (1-9 月)             月)
 一、经营活动产生的现金流量:
   销售商品、提供劳务收到的现金                               46,534,471.91       4,214,444.40
   收到的税费返还
   收到其他与经营活动有关的现金                              526,881,521.21    361,440,781.81
     经营活动现金流入小计                                    573,415,993.12    365,655,226.21
   购买商品、接受劳务支付的现金
   支付给职工以及为职工支付的现金                             58,693,527.83     52,628,316.38
   支付的各项税费                                              6,814,409.07       9,749,305.56
   支付其他与经营活动有关的现金                              391,245,025.34    792,770,186.10
     经营活动现金流出小计                                    456,752,962.24    855,147,808.04
   经营活动产生的现金流量净额                                116,663,030.88    -489,492,581.83
 二、投资活动产生的现金流量:
   收回投资收到的现金                                      1,509,139,670.83    400,000,000.00
   取得投资收益收到的现金                                    559,147,656.60    717,134,569.18
   处置固定资产、无形资产和其他长期资产收回的现金净额           401,224.28      88,172,000.00
   处置子公司及其他营业单位收到的现金净额
   收到其他与投资活动有关的现金                              981,488,556.99   1,509,616,411.98
     投资活动现金流入小计                                  3,050,177,108.70   2,714,922,981.16
   购建固定资产、无形资产和其他长期资产支付的现金             32,274,459.14     30,197,582.06
   投资支付的现金                                          1,500,000,000.00    700,000,000.00
   取得子公司及其他营业单位支付的现金净额                    218,657,250.00    383,612,034.83
   支付其他与投资活动有关的现金                               80,337,186.90    534,572,000.00
     投资活动现金流出小计                                  1,831,268,896.04   1,648,381,616.89
       投资活动产生的现金流量净额                          1,218,908,212.66   1,066,541,364.27
 三、筹资活动产生的现金流量:
   吸收投资收到的现金
   取得借款收到的现金                                      1,320,000,000.00    374,000,000.00

                                           19 / 20
                                   2015 年第三季度报告



  收到其他与筹资活动有关的现金
    筹资活动现金流入小计                                 1,320,000,000.00    374,000,000.00
  偿还债务支付的现金                                      370,000,000.00     360,000,000.00
  分配股利、利润或偿付利息支付的现金                      803,249,183.40     716,933,216.82
  支付其他与筹资活动有关的现金                                                 7,000,000.00
    筹资活动现金流出小计                                 1,173,249,183.40   1,083,933,216.82
      筹资活动产生的现金流量净额                          146,750,816.60    -709,933,216.82
四、汇率变动对现金及现金等价物的影响                        -4,362,063.52        451,982.03
五、现金及现金等价物净增加额                             1,477,959,996.62   -132,432,452.35
  加:期初现金及现金等价物余额                           2,495,427,524.95   2,273,739,724.18
六、期末现金及现金等价物余额                             3,973,387,521.57   2,141,307,271.83

法定代表人:楼定波         主管会计工作负责人:左敏          会计机构负责人:沈波




4.2 审计报告
□适用 √不适用




                                         20 / 20
数据加载中...
prevnext
手机查看股票